Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$234.61 USD

234.61
1,439,652

+2.97 (1.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $234.76 +0.15 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

National Vision (EYE) Q4 Revenues Miss Mark, Margins Down

by Zacks Equity Research

National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.

Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls

by Zacks Equity Research

Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.

Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.

BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.

Insulet (PODD) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

Inogen (INGN) Q4 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues in its domestic business-to-business sales channel.

OPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

DaVita (DVA) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Despite DaVita's (DVA) robust revenues in its Other segment, its overall Q4 performance was soft.

Merit Medical (MMSI) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in its Cardiovascular segment and the majority of product categories within its Cardiovascular unit.

Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.

BD's (BDX) Latest Combination Test Receives the FDA's EUA

by Zacks Equity Research

BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.

BDX vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

BDX vs. WST: Which Stock Is the Better Value Option?

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.61% and 0.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

MedTech Stocks' Earnings to Watch on Feb 2: BDX, DGX & CNMD

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.

Should You Buy Becton Dickinson (BDX) Ahead of Earnings?

by Zacks Equity Research

Becton Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Becton Dickinson (BDX) Could Beat Earnings Estimates Again

by Zacks Equity Research

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights Exxon Mobil, Fomento Economico Mexicano, Prologis, Marsh & McLennan and Becton Dickinson

by Zacks Equity Research

Exxon Mobil, Fomento Economico Mexicano, Prologis, Marsh & McLennan and Becton Dickinson are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Exxon Mobil, Fomento Economico Mexicano & Prologis

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Fomento Econmico Mexicano, S.A.B. de C.V. (FMX) and Prologis, Inc. (PLD).

BD's (BDX) New Robotic Track System to Boost Lab Workflow

by Zacks Equity Research

BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.

BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.